Page last updated: 2024-11-05

triclocarban

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Triclocarban is an antimicrobial agent commonly used in personal care products like soaps, shampoos, and toothpastes. It is synthesized by reacting 3,4-dichlorophenyl isocyanate with 2,4,6-trichlorophenol. Triclocarban has a broad spectrum of antibacterial activity, particularly against Gram-positive bacteria. However, its use has come under scrutiny due to concerns about potential adverse health effects, including endocrine disruption and antibiotic resistance. Its importance lies in its ability to reduce bacterial contamination and its potential to prevent infections. Research on triclocarban focuses on its environmental fate, ecotoxicity, and potential health risks to humans and wildlife.'

triclocarban: bacteriostat; antiseptic in soaps & other cleansing solns; germicide; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

triclocarban : A member of the class of phenylureas that is urea substituted by a 4-chlorophenyl group and a 3,4-dichlorophenyl group at positions 1 and 3 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7547
CHEMBL ID1076347
CHEBI ID48347
SCHEMBL ID68658
MeSH IDM0054336

Synonyms (140)

Synonym
AC-12602
n-(4-chlorophenyl)-n'-(3,4-dichlorophenyl)urea
wln: gr dmvmr cg dg
3,4'-trichlorocarbanilide
trilocarban
urea,4-dichlorophenyl)-
cusiter
cutisan
genoface
carbanilide,4,4'-trichloro-
n-(3,4-dichlorophenyl)-n'-(4-chlorophenyl)urea
ent 26925
cp 78416
TCC ,
3,4'-trichlorodiphenylurea
triclocarban
nsc-72005
procutene
trichlorocarbanilide
triclocarban (usp/inn)
D06223
bdbm25730
cid_7547
us8815951, 3-(4-chlorophenyl)-1-(3,4-dichlorophenyl)urea
urea-based compound, 11
3-(4-chlorophenyl)-1-(3,4-dichlorophenyl)urea
triclocarbanum [inn-latin]
c13h9cl3n2o
ai3-26925
brn 2814890
trichlorcarban
einecs 202-924-1
nsc 72005
tcc soap
epa pesticide chemical code 027901
ccris 4880
tcc (soap bacteriostat)
carbanilide, 3,4,4'-trichloro-
trichlocarban
caswell no. 874
triclocarban [usan:inn]
hsdb 5009
1-(4-chlorophenyl)-3-(3,4-dichlorophenyl)urea
101-20-2
nsc72005
urea, n-(4-chlorophenyl)-n'-(3,4-dichlorophenyl)-
3,4,4'-trichlorocarbanilide, 99%
NCGC00164034-01
NCIOPEN2_008923
CHEBI:48347 ,
solubacter
3,4,4'-trichlorodiphenylurea
3,4,4'-trichloro carbanilide
1-(3',4'-dichlorophenyl)-3-(4'-chlorophenyl)urea
3,4,4'-trichlorocarbanilide
triclocarbanum
MLS002415563
smr001339078
T1015
CHEMBL1076347
AKOS001713711
A800352
1-(4-chlorophenyl)-1-(3,4-dichlorophenyl)urea
NCGC00164034-04
NCGC00164034-03
NCGC00164034-02
STK730440
3,4,4-trichlorocarbanilide
dtxcid906214
NCGC00259579-01
NCGC00254243-01
dtxsid4026214 ,
cas-101-20-2
tox21_300481
tox21_112078
tox21_202030
bgg1y1ed0y ,
4-12-00-01265 (beilstein handbook reference)
unii-bgg1y1ed0y
ec 202-924-1
3,4,4 inverted exclamation marka-trichlorocarbanilide
FT-0614114
triclocarban [who-dd]
triclocarban [inn]
triclocarban [mart.]
triclocarban [hsdb]
triclocarban [inci]
triclocarban [usp monograph]
triclocarban [mi]
triclocarban [usan]
triclocarban [usp-rs]
S6444
SCHEMBL68658
NCGC00164034-05
tox21_112078_1
KS-5290
n-(4-chlorophenyl)-n'-(3,4-dichlorophenyl)-urea
Q-201865
nipaguard tcc
CS-7760
mfcd00013254
SR-01000860289-2
sr-01000860289
triclocarban, united states pharmacopeia (usp) reference standard
3,4,4` trichlorocarbanilide (triclocarban), pharmaceutical secondary standard; certified reference material
9eg ,
triclocarban, analytical standard
HY-B1805
DB11155
Q416579
E77179
(triclocarban)
3,?4,?4'-?trichlorocarbanilide
3,4,4'-trichlorocarbanilide(triclocarban)
EN300-7401785
triclocarban (mart.)
image essentials gold
triclocarban (usp-rs)
dollar general gold
1st date antibacterial deodorant (white)
1-(4-chlorophenyl)-3-(3,4-dichlorophenyl) urea
rite aid renewal gold deodorant
dial gold barantibacterial deodorant soap
antibacterial beauty
triclocarbanum (inn-latin)
triclocarban (usp monograph)
1st date antibacterial deodorant (green)
1st date antibacterial deodorant (gold)
triclorocarbanilide
antibacterial golden burst
dg bodyantibacterial deodorant 3.5 oz bar
dial aloealoe
dial odor armorodor armor
triclocarbanum (latin)
triclocarben
dialwhite
personal care antibacterial
antibacterial ocean fresh
megafresh antibacterial deodorant
coralite ultra antibacterial deodorant

Research Excerpts

Overview

Triclocarban (TCC) is an emerging and intractable environmental contaminant due to its hydrophobicity and chemical stability. It is a broad-spectrum antibacterial agent used globally, and high concentrations of this harmful chemical exist in the environment.

ExcerptReferenceRelevance
"Triclocarban is a highly effective and broadly used antimicrobial agent. "( Prenatal Exposure to Triclocarban Impairs ESR1 Signaling and Disrupts Epigenetic Status in Sex-Specific Ways as Well as Dysregulates the Expression of Neurogenesis- and Neurotransmitter-Related Genes in the Postnatal Mouse Brain.
Kajta, M; Maćkowiak, M; Pietrzak, BA; Przepiórska, K; Rzemieniec, J; Wnuk, A, 2021
)
2.38
"Triclocarban (TCC) is an emerging and intractable environmental contaminant due to its hydrophobicity and chemical stability. "( An amidase and a novel phenol hydroxylase catalyze the degradation of the antibacterial agent triclocarban by Rhodococcus rhodochrous.
Hou, N; Li, C; Li, D; Sun, G; Sun, S; Sun, Y; Zang, H; Zhao, X, 2022
)
2.38
"Triclocarban (TCC) is an emerging environmental contaminant, posing potential ecological risks. "( Response pathways of superoxide dismutase and catalase under the regulation of triclocarban-triggered oxidative stress in Eisenia foetida: Comprehensive mechanism analysis based on cytotoxicity and binding model.
Cui, Z; He, F; Huo, C; Li, X; Li, Y; Liu, R; Qi, Y; Tian, G; Wang, H; Zong, W, 2023
)
2.58
"Triclocarban (TCC) is a widely used environmental endocrine-disrupting chemical (EDC). "( Triclocarban triggers osteoarthritis via DNMT1-mediated epigenetic modification and suppression of COL2A in cartilage tissues.
Cao, J; Chen, X; Guo, H; He, L; Hong, A; Li, J; Su, Z; Wang, Z; Xie, J; Yang, Y; Ye, J; Yu, H; Zha, Z; Zhang, B; Zhang, P; Zhang, Y, 2023
)
3.8
"Triclocarban (TCC) is a broad-spectrum antibacterial agent used globally, and high concentrations of this harmful chemical exist in the environment. "( Acute exposure of triclocarban affects early embryo development in mouse through disrupting maternal-to-zygotic transition and epigenetic modifications.
Cao, YX; Chen, YW; Ding, ZM; Huo, LJ; Miao, YL; Wang, SK; Wang, YS; Yang, SJ; Zhang, SX, 2023
)
2.69
"Triclocarban (TCC), is an antimicrobial component in personal care products and it is one of the emerging contaminants since it has been detected in various environmental matrices. "( Early-life exposure to environmentally relevant concentrations of triclocarban impairs ocular development in zebrafish larvae.
Benedetti, E; Bertolucci, C; Cacciola, NA; Caioni, G; Colasante, M; d'Angelo, M; Fioravanti, G; Ippoliti, R; Lucon-Xiccato, T; Massimi, M; Merola, C; Perugini, M; Savaşçı, BB, 2023
)
2.59
"Triclocarban (TCC) is an antibacterial component widely used in personal care products with potential toxicity possessing public health issues. "( Triclocarban exposure aggravates dextran sulfate sodium-induced colitis by deteriorating the gut barrier function and microbial community in mice.
Cao, Z; Chen, C; Du, R; Lei, H; Qin, M; Song, Y; Wang, X; Wu, M; Zhang, C; Zhang, L, 2023
)
3.8
"Triclocarban (TCC) is a widely used broad-spectrum antimicrobial agent that has become a pollutant threatening the health of aquatic animals. "( Toxic effects of triclocarban on the histological morphology, physiological and immune response in the gills of the black tiger shrimp Penaeus monodon.
Duan, Y; Huang, J; Nan, Y; Xiao, M; Xing, Y; Yang, Y; Zhang, Z; Zhu, X, 2023
)
2.69
"Triclocarban (TCC) is a widely used antimicrobial ingredient in consumer products and is a ubiquitous contaminant in the environment. "( Triclocarban exposure exaggerates colitis and colon tumorigenesis: roles of gut microbiota involved.
Cao, X; Gu, M; Sanidad, KZ; Wang, W; Xiao, H; Xie, M; Yang, H; Zhang, G, 2020
)
3.44
"Triclocarban (TCC) is an antimicrobial compound widely used in personal care products such as soaps, toothpaste, and shampoo. "( In utero and lactational exposure to triclocarban: reproductive effects on female rat offspring.
Anselmo Franci, JA; Borges, LI; Cavalcanti, LF; Costa, NO; Gerardin, DCC; Kiss, ACI; Montagnini, BG, 2020
)
2.27
"Triclocarban (TCC) is a highly effective antibacterial agent, which is widely used in a variety of applications and present at significant levels (e.g., 760 μg/L) in wastewater worldwide. "( The fate and impact of TCC in nitrifying cultures.
Bian, Y; Li, H; Liu, X; Liu, Y; Ni, BJ; Wang, D; Wang, Q; Yang, Q; Zhang, Y, 2020
)
2
"Triclocarban (TCC) is an antimicrobial compound, widely used in personal care products, such as soaps, toothpaste, and shampoo. "( In utero and lactational exposure to triclocarban: Age-associated changes in reproductive parameters of male rat offspring.
Cavichioli, AM; Costa, NO; Forcato, S; Gerardin, DCC; Pereira, MRF, 2020
)
2.27
"Triclocarban (TCC) is a contaminant of emerging concern widely applied as an antimicrobial in personal care products and introduced into the terrestrial environment through the application of biosolids (i.e., treated sewage sludge) in agriculture. "( Triclocarban affects earthworms during long-term exposure: Behavior, cytotoxicity, oxidative stress and genotoxicity assessments.
Correia, FV; de Farias Araujo, G; Oliveira da Silva, E; Saggioro, EM; Sales Junior, SF; Soares, LOS; Vallerie, Q, 2020
)
3.44
"Triclocarban (TCC) is an antibacterial agent found in pharmaceuticals and personal care products (PPCP). "( Triclocarban: UV photolysis, wastewater disinfection, and ecotoxicity assessment using molecular biomarkers.
Buss, DF; de Paiva Magalhães, D; Oliveira, A; Saggioro, EM; Satyro, S; Veríssimo, F, 2017
)
3.34
"Triclocarban is a phenyl ether that has recently been classified as a contaminant of emerging concern. "( Triclocarban Disrupts the Epigenetic Status of Neuronal Cells and Induces AHR/CAR-Mediated Apoptosis.
Chwastek, E; Kajta, M; Lason, W; Mackowiak, M; Nehring, I; Rzemieniec, J; Staniszewska, M; Wnuk, A; Wojtowicz, AK, 2019
)
3.4
"Triclocarban (TCC) is an antibacterial agent commonly found in environmental, wildlife, and human samples. "( Triclocarban at environmentally relevant concentrations induces the endoplasmic reticulum stress in zebrafish.
Hu, Z; Li, Y; Liu, C; Su, Y; Wei, J; Yuan, H; Zhang, H; Zhao, K; Zhou, T, 2019
)
3.4
"Triclocarban (TCC) is an antimicrobial agent that is used in detergents, soaps and other personal hygiene products. "( Effects of triclocarban on the transcription of estrogen, androgen and aryl hydrocarbon receptor responsive genes in human breast cancer cells.
Hunecke, D; Luch, A; Tarnow, P; Tralau, T, 2013
)
2.22
"Triclocarban (TCC) is an antimicrobial used in personal hygiene products. "( Triclocarban-induced change in intracellular Ca²⁺ level in rat thymocytes: cytometric analysis with Fluo-3 under Zn²⁺-free conditions.
Chen, X; Enkhjargal, M; Kuroda, K; Miura, Y; Oyama, Y; Satoh, M; Sugihara, A; Sun, Y; Yamada, S, 2014
)
3.29
"Triclocarban (TCC) is an antimicrobial agent routinely detected in surface waters that has been hypothesized to interact with the vertebrate endocrine system. "( Effects of the antimicrobial contaminant triclocarban, and co-exposure with the androgen 17β-trenbolone, on reproductive function and ovarian transcriptome of the fathead minnow (Pimephales promelas).
Ankley, GT; Cavallin, JE; Durhan, EJ; Garcia-Reyero, N; Jensen, KM; Kahl, MD; Leino, RL; Makynen, EA; Perkins, EJ; Villeneuve, DL; Wehmas, LC, 2017
)
2.16
"Triclocarban (TCC) is an emerging and persistent pollutant once released into environment. "( Role of plant growth-promoting Ochrobactrum sp. MC22 on triclocarban degradation and toxicity mitigation to legume plants.
Sipahutar, MK; Vangnai, AS, 2017
)
2.14
"Triclocarban is an antimicrobial and antibacterial agent found in personal care products and subsequently is a prevalent wastewater contaminant. "( Quantitative determination of triclocarban in wastewater effluent by stir bar sorptive extraction and liquid desorption-liquid chromatography-tandem mass spectrometry.
Flannelly, DF; Klein, DR; Schultz, MM, 2010
)
2.09
"Triclocarban (TCC) is an antibacterial compound commonly detected in biosolids at parts-per-million concentrations. "( Fate of 14C-triclocarban in biosolids-amended soils.
McAvoy, DC; O'Connor, GA; Snyder, EH, 2010
)
2.18
"Triclocarban (TCC) is an active ingredient in antibacterial bar soaps, a common constituent of domestic wastewater, and the subject of recent criticism by consumer advocate groups and academic researchers alike. "( Measured physicochemical characteristics and biosolids-borne concentrations of the antimicrobial Triclocarban (TCC).
McAvoy, DC; O'Connor, GA; Snyder, EH, 2010
)
2.02
"Triclocarban (TCC) is an antimicrobial additive of personal care products that is only partially degraded during wastewater treatment. "( Identification of wastewater bacteria involved in the degradation of triclocarban and its non-chlorinated congener.
Colquhoun, DR; Halden, RU; Miller, TR, 2010
)
2.04
"Triclocarban is an antiseptic of the anilide family. "( [Triclocarban antibacterial activity on resistant staphylococci, streptococci, and enterococci].
Drugeon, HB; Michaud-Nerard, A; Rouveix, B, 2012
)
2.73

Effects

Triclocarban (TCC) has a high detection frequency in soil, rivers, sediments, and organisms. The effects of short-term TCC exposure on cardiac function are not known.

ExcerptReferenceRelevance
"Triclocarban (TCC) has a high detection frequency in soil, rivers, sediments, and organisms, and its ecological risks have attracted substantial attention. "( Fate and biodegradation characteristics of triclocarban in wastewater treatment plants and sewage sludge composting processes and risk assessment after entering the ecological environment.
Chen, T; Ma, C; Wang, Y; Yu, B; Zheng, G, 2021
)
2.33
"Triclocarban (TCC) has been used in consumer products and is a widespread contaminant in municipal wastewater treatment systems that ultimately accumulates in natural receiving water and soil. "( Triclocarban-contaminated wastewater treatment by innovative hybrid moving entrapped bead activated sludge reactor (HyMER): Continuous performance and computational dynamic simulation analysis.
Radpukdee, T; Ratpukdi, T; Siripattanakul-Ratpukdi, S; Sonsuphab, K; Sucharitpwatskul, S; Suriyawanakul, J; Taweetanawanit, P; Therdkiattikul, N, 2023
)
3.8
"Triclocarban (TCC) has a high detection frequency in soil, rivers, sediments, and organisms, and its ecological risks have attracted substantial attention. "( Fate and biodegradation characteristics of triclocarban in wastewater treatment plants and sewage sludge composting processes and risk assessment after entering the ecological environment.
Chen, T; Ma, C; Wang, Y; Yu, B; Zheng, G, 2021
)
2.33
"Triclocarban has been widely used for over 50 years, but only recently some concerns were raised about its endocrine disruptive properties."( The Different Facets of Triclocarban: A Review.
Catalano, A; Ceramella, J; Drommi, D; Iacopetta, D; Ielo, I; Plutino, MR; Rosace, G; Salvagno, L; Saturnino, C; Scali, E; Sinicropi, MS, 2021
)
1.65
"Triclocarban (TCC) has been identified as a new environmental pollutant that is potentially hazardous to human health; however, the effects of short-term TCC exposure on cardiac function are not known. "( Metabonomics Indicates Inhibition of Fatty Acid Synthesis, β-Oxidation, and Tricarboxylic Acid Cycle in Triclocarban-Induced Cardiac Metabolic Alterations in Male Mice.
Chen, H; Cui, Y; Li, H; Li, W; Ren, J; Shen, G; Xie, W; Yu, W; Zhang, W; Zhang, Z; Zhou, L; Zhuang, X, 2018
)
2.14
"Triclocarban (TCC) has been reported as a persistent, high production volume chemical with the potential to bioaccumulate in the environment."( Fate of triclocarban during soil aquifer treatment: soil column studies.
Amy, G; Brdjanovic, D; Essandoh, HM; Mohamed, MH; Tizaoui, C, 2010
)
1.52

Actions

ExcerptReferenceRelevance
"Triclocarban exposure may increase the risk of T2DM in the women, although additional studies are needed to confirm the results of this study and to investigate the underlying mechanisms."( Association between triclocarban and triclosan exposures and the risks of type 2 diabetes mellitus and impaired glucose tolerance in the National Health and Nutrition Examination Survey (NHANES 2013-2014).
Du, X; Feng, L; Hao, G; Huang, X; Jing, C; Liang, J; Liu, D; Liu, K; Lu, C; Wen, Z; Wu, M; Xie, X; Yang, G; Ying, Y; Zheng, S, 2020
)
2.32

Toxicity

ExcerptReferenceRelevance
" The toxicities of biosolids-borne TCC to Eisenia fetida earthworms and soil microbial communities were characterized using adaptations of the USEPA Office of Prevention, Pesticides, and Toxic Substances (OPPTS) Guidelines 850."( Toxicity and bioaccumulation of biosolids-borne triclocarban (TCC) in terrestrial organisms.
McAvoy, DC; O'Connor, GA; Snyder, EH, 2011
)
0.62
" As results of toxicity tests, TCS was found to be most strongly toxic for green algae [e."( Ecotoxicity and screening level ecotoxicological risk assessment of five antimicrobial agents: triclosan, triclocarban, resorcinol, phenoxyethanol and p-thymol.
Kagota, K; Kameda, Y; Kimura, K; Morita, J; Nakada, N; Tamura, I; Tatarazako, N; Yamamoto, H; Yasuda, Y; Yoneda, S, 2013
)
0.6
" The present study investigates whether exposure of 6 plant species (radish, carrot, soybean, lettuce, spring wheat, and corn) to triclosan or triclocarban derived from biosolids has an adverse effect on seed emergence and/or plant growth parameters."( Toxicity of biosolids-derived triclosan and triclocarban to six crop species.
Lissemore, L; Prosser, RS; Sibley, PK; Solomon, KR, 2014
)
0.86
"The information about adverse effects of emerging contaminants on aquatic protozoa is very scarce."( Effects of triclosan and triclocarban on the growth inhibition, cell viability, genotoxicity and multixenobiotic resistance responses of Tetrahymena thermophila.
Ao, J; Bai, Q; Cheng, P; Gao, L; Wang, W; Yuan, T; Zhang, H; Zhou, C, 2015
)
0.72
" In the single-substance tests, TCC was about 30 times more toxic than TCS when considering effects on growth and concerning reproduction, TCC was about 50 times more toxic than TCS."( The toxicity of a mixture of two antiseptics, triclosan and triclocarban, on reproduction and growth of the nematode Caenorhabditis elegans.
Spann, N; Vingskes, AK, 2018
)
0.72
" PCPs are biologically active substances that can exert an adverse effect on the ecology and food safety."( Occurrence and Safety Evaluation of Antimicrobial Compounds Triclosan and Triclocarban in Water and Fishes of the Multitrophic Niche of River Torsa, India.
Aftabuddin, M; Bandyopadhyay, S; Das Sarkar, S; Das, BK; Kumari, K; Nag, SK; Saha, K, 2020
)
0.79
" Displaying a high accumulation effect and 120-day half-life in the soil environment, the toxic effects of TCC to soil organisms have been widely reported."( Response pathways of superoxide dismutase and catalase under the regulation of triclocarban-triggered oxidative stress in Eisenia foetida: Comprehensive mechanism analysis based on cytotoxicity and binding model.
Cui, Z; He, F; Huo, C; Li, X; Li, Y; Liu, R; Qi, Y; Tian, G; Wang, H; Zong, W, 2023
)
1.14
" However, the toxic effects of TCC on Penaeus monodon are still lacking."( Toxic effects of triclocarban on the histological morphology, physiological and immune response in the gills of the black tiger shrimp Penaeus monodon.
Duan, Y; Huang, J; Nan, Y; Xiao, M; Xing, Y; Yang, Y; Zhang, Z; Zhu, X, 2023
)
1.25

Compound-Compound Interactions

ExcerptReferenceRelevance
"In this study, dispersive liquid-liquid microextraction (DLLME) combined with ultra-high-pressure liquid chromatography (UHPLC)-tunable ultraviolet detection (TUV), has been developed for pre-concentration and determination of triclosan (TCS), triclocarban (TCC) and methyl-triclosan (M-TCS) in aqueous samples."( Determination of triclosan, triclocarban and methyl-triclosan in aqueous samples by dispersive liquid-liquid microextraction combined with rapid liquid chromatography.
Cao, XL; Guo, JH; Li, XH; Li, Y; Wang, XZ; Xu, XB, 2009
)
0.83

Bioavailability

ExcerptReferenceRelevance
" The extent of biosolids-borne TCC environmental transport and potential human/ecological exposures will be greatly affected by its bioavailability and the rate of degradation in amended soils."( Fate of 14C-triclocarban in biosolids-amended soils.
McAvoy, DC; O'Connor, GA; Snyder, EH, 2010
)
0.74
" However, these data also suggest substantially reduced bioavailability of TCC in biosolids-amended soils compared with HOC partitioning theory."( Persistence of triclocarban and triclosan in soils after land application of biosolids and bioaccumulation in Eisenia foetida.
Chalew, TE; Halden, RU; Higgins, CP; Hundal, LS; Paesani, ZJ, 2011
)
0.72
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
" Accumulation of TCC in organisms depends on the lipophilicity and bioavailability of TCC in sediment and water."( Fate of Triclocarban (TCC) in aquatic and terrestrial systems and human exposure.
Pugazhendhi, A; Seethappan, S; Vimalkumar, K, 2019
)
0.95
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Metabolic transformations play critical roles in the bioavailability and toxicities of environmental pollutants and toxicants."( Metabolic fate of environmental chemical triclocarban in colon tissues: roles of gut microbiota involved.
Ai, L; Cai, Z; Haggerty, TD; Parsonnet, J; Sanidad, KZ; Wang, G; Xie, M; Yang, H; Yeliseyev, V; Zhang, G; Zhang, H; Zhang, J, 2021
)
0.89

Dosage Studied

ExcerptRelevanceReference
" The authors' results show that the molecular estrogenic effects of triclocarban are eliminated (males) or reversed (females) when dosed in conjunction with several other PPCP, once again demonstrating that results from single exposures could be vastly different from those observed with mixtures."( Effects of triclocarban, N,N-diethyl-meta-toluamide, and a mixture of pharmaceuticals and personal care products on fathead minnows (Pimephales promelas).
Archuleta, LC; Sanchez, BC; Sepulveda, MS; Zenobio, JE, 2014
)
1.03
" Increasing carbon dosage and contact time enhanced the removal of micropollutants."( Adsorption characteristics of selected hydrophilic and hydrophobic micropollutants in water using activated carbon.
Choi, DJ; Her, N; Kim, SK; Nam, SW; Zoh, KD, 2014
)
0.4
" While AChE showed a dose-response curve (with a significant increased activity at a TCC concentration of 2500ng/L), oxidative stress markers did not follow a dose-response curve, with significant increase at 100 and/or 500ng/L and a decreased activity in the highest concentration (2500ng/L)."( Chronic effects of triclocarban in the amphipod Gammarus locusta: Behavioural and biochemical impairment.
Barros, S; Montes, R; Neuparth, T; Oliveira, JMA; Quintana, JB; Rodil, R; Santos, MM, 2017
)
0.78
" Enzymatic hydrolysis of the samples was optimized based on enzyme dosage and incubation time."( Simultaneous determination of triclosan, triclocarban, triclocarban metabolites and byproducts in urine and serum by ultra-high-performance liquid chromatography/electrospray ionization tandem mass spectrometry.
Cai, Z; Liu, Z; Luo, Q; Zhang, H; Zhou, Y, 2021
)
0.89
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
disinfectantAn antimicrobial agent that is applied to non-living objects to destroy harmful microorganisms or to inhibit their activity.
antiseptic drugA substance used locally on humans and other animals to destroy harmful microorganisms or to inhibit their activity (cf. disinfectants, which destroy microorganisms found on non-living objects, and antibiotics, which can be transported through the lymphatic system to destroy bacteria within the body).
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
phenylureasAny member of the class of ureas in which at least one of the nitrogens of the urea moiety is substituted by a phenyl or substituted phenyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (63)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency7.58760.007215.758889.3584AID1224835; AID588342; AID624030
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624417
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency24.39873.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency15.95950.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency16.93010.173734.304761.8120AID1346924
ATAD5 protein, partialHomo sapiens (human)Potency11.57740.004110.890331.5287AID504467
SMAD family member 3Homo sapiens (human)Potency16.93010.173734.304761.8120AID1346924
TDP1 proteinHomo sapiens (human)Potency2.84570.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency13.01340.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency16.66160.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
Smad3Homo sapiens (human)Potency11.60470.00527.809829.0929AID588855; AID720534; AID720536; AID720537
PINK1Homo sapiens (human)Potency13.35732.818418.895944.6684AID624263
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency5.94500.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency3.98350.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency12.13470.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency31.62280.01237.983543.2770AID1346984
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency3.68450.000214.376460.0339AID588533; AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency2.02040.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency4.50710.000817.505159.3239AID1159527; AID1159531; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency8.51390.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency17.70580.375827.485161.6524AID588526; AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency7.41580.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency12.90960.000229.305416,493.5996AID1259244; AID1259248; AID588513; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency4.36490.01238.964839.8107AID1645842
67.9K proteinVaccinia virusPotency13.01510.00018.4406100.0000AID720579; AID720580
ParkinHomo sapiens (human)Potency13.35730.819914.830644.6684AID624263
P53Homo sapiens (human)Potency28.18380.07319.685831.6228AID504706
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency13.58310.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency23.41810.001019.414170.9645AID588536; AID588537; AID743094; AID743191
IDH1Homo sapiens (human)Potency18.35640.005210.865235.4813AID686970
aryl hydrocarbon receptorHomo sapiens (human)Potency4.56250.000723.06741,258.9301AID651777; AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency11.30520.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency21.44380.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259395
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency19.493819.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency9.80610.057821.109761.2679AID1159526; AID1159528
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency5.62340.01262.451825.0177AID485313
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.00250.010039.53711,122.0200AID588547
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency22.38720.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency2.56520.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency21.68990.037617.082361.1927AID1259364
huntingtin isoform 2Homo sapiens (human)Potency11.22020.000618.41981,122.0200AID1688
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency6.41370.000627.21521,122.0200AID743202; AID743219
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency28.18380.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency28.18380.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency28.18380.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency13.53450.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency8.32280.005612.367736.1254AID624032; AID624044
lamin isoform A-delta10Homo sapiens (human)Potency11.22020.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency16.85410.001557.789015,848.9004AID1259244
Glycoprotein hormones alpha chainHomo sapiens (human)Potency11.22024.46688.344810.0000AID624291
Interferon betaHomo sapiens (human)Potency17.01910.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency4.36490.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency7.88670.002319.595674.0614AID651631; AID651743; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency16.85410.001551.739315,848.9004AID1259244
Alpha-synucleinHomo sapiens (human)Potency0.81550.56239.398525.1189AID652106
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency35.48130.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency4.36490.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency4.36490.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NLRP3 proteinHomo sapiens (human)IC50 (µMol)1.14750.64007.081131.0000AID488799; AID488800
Bifunctional epoxide hydrolase 2Homo sapiens (human)IC50 (µMol)0.01300.00000.54509.1000AID613884
Epoxide hydrolase BMycobacterium tuberculosis CDC1551IC50 (µMol)0.22000.01900.66403.4000AID1798579; AID613896
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (260)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
response to toxic substanceBifunctional epoxide hydrolase 2Homo sapiens (human)
positive regulation of gene expressionBifunctional epoxide hydrolase 2Homo sapiens (human)
dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
cholesterol homeostasisBifunctional epoxide hydrolase 2Homo sapiens (human)
stilbene catabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
phospholipid dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
regulation of cholesterol metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (80)

Processvia Protein(s)Taxonomy
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
magnesium ion bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide hydrolase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
toxic substance bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lipid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein homodimerization activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lysophosphatidic acid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (55)

Processvia Protein(s)Taxonomy
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomal matrixBifunctional epoxide hydrolase 2Homo sapiens (human)
cytosolBifunctional epoxide hydrolase 2Homo sapiens (human)
extracellular exosomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (108)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1211630Drug metabolism assessed as human UGT1A3-mediated N'-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211597Drug metabolism assessed as human UGT1A9-mediated N-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 30 mins by LC-ESI-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211617Drug metabolism assessed as human UGT1A9-mediated N-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211604Drug metabolism in B6C3F1 mouse liver microsomes assessed as N'-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 30 mins by LC-UV-ESI-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID580920Cytotoxicity against human Raji cells after 72 hrs by Cell titer-glo assay2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Evaluation of Diarylureas for Activity Against Plasmodium falciparum.
AID1211657Drug metabolism in cynomolgus monkey liver microsomes assessed as N-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211636Drug metabolism assessed as human UGT1A10-mediated N'-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211638Drug metabolism assessed as human UGT2B7-mediated N'-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211615Drug metabolism assessed as human UGT1A7-mediated N-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211641Drug metabolism in cynomolgus monkey liver microsomes assessed as N-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 30 mins by LC-UV-ESI-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211598Drug metabolism assessed as human UGT1A9-mediated N'-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 30 mins by LC-ESI-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211610Drug metabolism in human intestinal microsomes assessed as N-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211609Drug metabolism in human kidney microsomes assessed as N-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211624Drug metabolism in human liver microsomes assessed as N'-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211603Drug metabolism in cynomolgus monkey liver microsomes assessed as N'-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 30 mins by LC-UV-ESI-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211643Drug metabolism in B6C3F1 mouse liver microsomes assessed as N-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 30 mins by LC-UV-ESI-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID580917Cytotoxicity against human BJ cells after 72 hrs by Cell titer-glo assay2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Evaluation of Diarylureas for Activity Against Plasmodium falciparum.
AID1211625Drug metabolism in cynomolgus monkey liver microsomes assessed as N'-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211633Drug metabolism assessed as human UGT1A7-mediated N'-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211591Drug excretion in Sprague-Dawley rat urine assessed as N-glucuronide-triclocarban formation at 1 mg/kg, po by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211621Drug metabolism assessed as human UGT2B15-mediated N-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211622Drug metabolism assessed as human UGT2B17-mediated N-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211663Drug metabolism in microsomes (unknown origin) assessed as retention time at 10 uM by LC-UV-MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID613896Inhibition of Mycobacterium tuberculosis recombinant EphB expressed in Escherichia coli BL21 using CMNPC as substrate after 30 mins by fluorescent assay relative to control2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID1211620Drug metabolism assessed as human UGT2B7-mediated N-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID580919Cytotoxicity against human HepG2 cells after 72 hrs by Cell titer-glo assay2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Evaluation of Diarylureas for Activity Against Plasmodium falciparum.
AID1211601Drug metabolism in human kidney microsomes assessed as N-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 30 mins by LC-UV-ESI-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211632Drug metabolism assessed as human UGT1A6-mediated N'-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211588Drug excretion in Swiss webster mouse urine assessed as 3'-O-glucuronide-triclocarban formation at 5 mg/kg, po by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211628Drug metabolism in human intestine microsomes assessed as N'-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211642Drug metabolism in human liver microsomes assessed as N-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 30 mins by LC-UV-ESI-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID580918Cytotoxicity against human HEK293 cells after 72 hrs by Cell titer-glo assay2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Evaluation of Diarylureas for Activity Against Plasmodium falciparum.
AID1211613Drug metabolism assessed as human UGT1A4-mediated N-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211634Drug metabolism assessed as human UGT1A8-mediated N'-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211635Drug metabolism assessed as human UGT1A9-mediated N'-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211592Drug excretion in Sprague-Dawley rat urine assessed as N'-glucuronide-triclocarban formation at 1 mg/kg, po by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211626Drug metabolism in B6C3F1 mouse liver microsomes assessed as N'-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211605Drug metabolism in human kidney microsomes assessed as N'-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 30 mins by LC-UV-ESI-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211661Drug excretion in monkey urine2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211586Drug excretion in Swiss webster mouse urine assessed as N'-glucuronide-triclocarban formation at 5 mg/kg, po by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211623Drug metabolism in Sprague-Dawley rat liver microsomes assessed as N'-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211660Drug excretion in human urine2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211619Drug metabolism assessed as human UGT2B4-mediated N-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211656Drug metabolism in human liver microsomes assessed as N-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211658Drug metabolism in B6C3F1 mouse liver microsomes assessed as N-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211631Drug metabolism assessed as human UGT1A4-mediated N'-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211593Drug excretion in Sprague-Dawley rat urine assessed as 2'-O-glucuronide-triclocarban formation at 1 mg/kg, po by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211627Drug metabolism in human kidney microsomes assessed as N'-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211612Drug metabolism assessed as human UGT1A3-mediated N-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211602Drug metabolism in human liver microsomes assessed as N'-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 30 mins by LC-UV-ESI-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211659Inhibition of human recombinant soluble epoxide hydrolase using CMNPC as substrate2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211616Drug metabolism assessed as human UGT1A8-mediated N-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211589Drug excretion in Swiss webster mouse urine assessed as 6-O-glucuronide-triclocarban formation at 5 mg/kg, po by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211655Drug metabolism in Sprague-Dawley rat liver microsomes assessed as N-glucuronide-triclocarban formation incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID613884Inhibition of human recombinant soluble epoxide hydrolase using CMNPC as substrate after 10 mins by fluorescent assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID1211587Drug excretion in Swiss webster mouse urine assessed as 2'-O-glucuronide-triclocarban formation at 5 mg/kg, po by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211614Drug metabolism assessed as human UGT1A6-mediated N-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211618Drug metabolism assessed as human UGT1A10-mediated N-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211595Drug excretion in Sprague-Dawley rat urine assessed as 6-O-glucuronide-triclocarban formation at 1 mg/kg, po by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211585Drug excretion in Swiss webster mouse urine assessed as N-glucuronide-triclocarban formation at 5 mg/kg, po by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211640Drug metabolism assessed as human UGT2B17-mediated N'-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211594Drug excretion in Sprague-Dawley rat urine assessed as 3'-O-glucuronide-triclocarban formation at 1 mg/kg, po by LC-MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID613895Selectivity index, ratio of IC50 for african green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
The structure-activity relationship of urea derivatives as anti-tuberculosis agents.
AID1211639Drug metabolism assessed as human UGT2B15-mediated N'-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211629Drug metabolism assessed as human UGT1A1-mediated N'-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211637Drug metabolism assessed as human UGT2B4-mediated N'-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID1211611Drug metabolism assessed as human UGT1A1-mediated N-glucuronide-triclocarban formation expressed in baculovirus infected insect sf9 cells incubated for 5 mins prior to UDPGA addition measured after 5 to 30 mins by LC-UV analysis2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro glucuronidation of the antibacterial triclocarban and its oxidative metabolites.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1798579Mtb EHB Inhibition Assay from Article 10.1016/j.jmb.2008.06.030: \\The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor.\\2008Journal of molecular biology, Sep-12, Volume: 381, Issue:4
The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (355)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (5.63)18.7374
1990's2 (0.56)18.2507
2000's31 (8.73)29.6817
2010's203 (57.18)24.3611
2020's99 (27.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.45 (24.57)
Research Supply Index5.92 (2.92)
Research Growth Index6.01 (4.65)
Search Engine Demand Index82.82 (26.88)
Search Engine Supply Index2.15 (0.95)

This Compound (49.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (1.92%)5.53%
Reviews9 (2.47%)6.00%
Case Studies2 (0.55%)4.05%
Observational1 (0.27%)0.25%
Other346 (94.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Triclosan, Triclocarban, and the Microbiota [NCT01509976]20 participants (Actual)Interventional2011-07-01Completed
Effect of Surfactants on the Skin Microbiome [NCT01951391]10 participants (Actual)Interventional2013-09-30Completed
Analysis of the Effect of Antimicrobial Soap on Bacterial Survival [NCT02012348]30 participants (Actual)Interventional2013-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01951391 (2) [back to overview]Relative 16S Abundance - Control Soap
NCT01951391 (2) [back to overview]Relative Abundance of Staphylococcus Epidermidis of Intervention Arms
NCT02012348 (2) [back to overview]Relative GAS Survival
NCT02012348 (2) [back to overview]Relative GAS Survival

Relative 16S Abundance - Control Soap

Total bacterial DNA abundance at baseline (relative to baseline), prior to washing with control soap (softsoap aquarium series hand soap) as measured by qPCR of 16S RNA (NCT01951391)
Timeframe: Baseline, 10 minutes, 6 hours, 24 hours

InterventionPercentage of Baseline (Mean)
Baseline10 Minutes6 Hours24 Hours
Control Hand Soap1007484100

[back to top]

Relative Abundance of Staphylococcus Epidermidis of Intervention Arms

Total bacterial DNA abundance of S. epidermidis (relative to baseline) at baseline and 6 hours, before washing with any soap as measured by qPCR of 16S RNA (NCT01951391)
Timeframe: Baseline, 6 hours

,,
InterventionPercentage of Baseline (Mean)
Baseline6 Hours
Benzalkonium Chloride Soap100100
Control Hand Soap100283
Triclocarban Soap100200

[back to top]

Relative GAS Survival

A skin swab will be used to measure the bacterial survival 1 hour after bacteria application (2 hours post washing with soap). The bacteria being applied and subsequently measured is Group A Streptococcus (GAS). The bacterial survival is expressed as abundance of GAS relative to abundance of other bacterial species isolated from the swab. (NCT02012348)
Timeframe: 1 hour after bacteria application / 2 hours post washing

Interventionpercentage overall bacterial abundance (Mean)
Control Soap100
Antibacterial Soap With Triclocarban86.7
Antibacterial Soap + Benzalkonium Chloride61.7

[back to top]

Relative GAS Survival

A skin swab will be used to measure the bacterial survival 30 minutes after bacteria application and soap treatment. The bacteria being applied and subsequently measured is Group A Streptococcus (GAS). The bacterial survival is expressed as abundance of GAS relative to abundance of other bacterial species isolated from the swab. (NCT02012348)
Timeframe: 30 minutes post-bacteria application

Interventionpercentage overall bacterial abundance (Mean)
Control Soap100
Antibacterial Soap With Triclocarban75
Antibacterial Soap + Benzalkonium Chloride90

[back to top]